TD Cowen Reaffirms Their Buy Rating on Evolent Health (EVH)
What's Next for Health Insurers as Medicare Finalizes 2025 Star Ratings?
Evolent To Release Third Quarter 2024 Financial Results on Thursday, November 7, 2024
Express News | Evolent Health Inc : Keybanc Initiates Coverage With Overweight Rating; Price Target $35
Evolent Health Inc (EVH) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Market ...
Evolent Health Shows Long-Term Growth Prospects Despite Humana, Cigna Combination Uncertainty, RBC Says
Expert Outlook: Evolent Health Through The Eyes Of 7 Analysts
Evolent Health Analyst Ratings
RBC Capital Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $42
Evolent Health (NYSE:EVH) Shareholders Are Still up 260% Over 5 Years Despite Pulling Back 4.0% in the Past Week
TD Cowen Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $63
TD Cowen Sticks to Their Buy Rating for Evolent Health (EVH)
J.P. Morgan Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $45
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $33
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating, Announces Target Price $33
Barclays Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $39
AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio?
JMP Securities Maintains Evolent Health(EVH.US) With Buy Rating, Raises Target Price to $43
JMP Securities analyst Constantine Davides maintains $Evolent Health(EVH.US)$ with a buy rating, and adjusts the target price from $31 to $43.According to TipRanks data, the analyst has a success
Evolent Health Buy Rating Affirmed With Increased Price Target Amid Growth Prospects and M&A Speculation
Evolent Health (NYSE:EVH) Pulls Back 5.1% This Week, but Still Delivers Shareholders Incredible 33% CAGR Over 5 Years